Full-Time

Director of Product Management

Consumables

Tandem Diabetes Care

Tandem Diabetes Care

1,001-5,000 employees

Develops subcutaneous insulin pumps and software

Compensation Overview

$190k - $215k/yr

+ Bonus

No H1B Sponsorship

Del Mar, CA, USA

Hybrid

Hybrid role; in-office at Del Mar, CA HQ as needed.

Category
Product (2)
,
Required Skills
Agile
Product Management
Data Analysis
Requirements
  • 12 years related experience in a combination of product management, product development, and/or product planning.
  • 7 years of experience in a direct or indirect leadership role with visibility to senior management.
  • Direct work experience delivering commercial products and services, ideally in consumer facing medical devices.
  • Bachelor’s degree (B.A/B.S.) in related field or combination of equivalent education and applicable work experience.
  • Degrees in engineering, information technology, data sciences or health sciences disciplines, preferred.
  • Degrees in product management, business administration, economics, mathematics, or related fields will be considered with sufficient career experience in the product management field.
  • Experience with educating and interacting with physician and other clinical stakeholders.
  • Excellent knowledge, experience, and track record of success related to product management, strategic planning, and the product development process for connected medical and health management devices, with hands-on experience of Agile and waterfall development methodologies.
  • Experience delivering product offerings across integrated systems encompassing hardware and software components; strong knowledge of underlying technologies.
  • Understanding of clinical and regulatory processes and requirements as it relates to product development and delivery; Direct experience operating within an FDA regulated environment.
  • Ability to distill complex requirements from multiple stakeholders to simple concepts and optimized solutions.
  • Ability to communicate fluently with engineering teams and translate to non-technical users.
  • Deep curiosity combined with excellent problem-solving skills and strong business sense.
  • Adept at creating and communicating a clear vision and expectations among team members to effectively align resources to achieve functional area goals.
  • Proven ability to operate in a matrixed environment and exert influence across multiple layers of the organization.
  • Foundational knowledge in the following disciplines: Clinical and regulatory, reimbursement, product development, product marketing, operations, quality, user experience and financial planning.
  • Deep data analytics capabilities
  • Advanced computer and computer software skills, to include Microsoft Office products, CRM, and proprietary databases.
Responsibilities
  • Leads the team responsible for the definition, launch and ongoing management of Tandem’s internal consumables programs.
  • Defines strategies and priorities for teams and cross functional collaborators and evolve an informed strategy and roadmap.
  • Functions as the internal champion for Tandem’s consumables and as the primary contact for related roadmap and strategy questions.
  • Establishes clinical Key Opinion Leaders, external research collaborators, policy makers, and regulatory bodies to create a strong network and drive ideation/creation of industry state of the art intelligence.
  • Identifies market needs and user requirements by gathering voice of customer (VOC) information and creates plans for the development and launch of new products supported by robust business cases.
  • Creates short, medium, and long- term roadmaps that provide direction for project prioritization and investment.
  • Works closely with Clinical Affairs and Regulatory Affairs to develop coordinated approaches to clinical studies and alignment on regulatory requirements.
  • Engages with and supports Down Stream Product Marketing, Sales and Customer Care to develop go-to-market strategies for new and in-market products, including plans for appropriate product education and training for HCPs and patients.
  • Creates opportunities to work with external partners to deliver on product and strategic objectives.
  • Represents the company and product category during medical conferences, sales meetings, and customer visits as required by commercial teams.
  • Monitors the product implications of competitive activity, market drivers, product KPIs, and external constraints and provides pertinent updates to management.
  • Supports the short-term planning for the department including headcount, budgeting, training, and systems requirements.
  • Supports the creation and maintenance of long-term forecasts for existing and new products offerings.
  • Participates in the selection, development, performance appraisal, merit recommendation, and promotion of staff.
  • Ensures department staff is properly trained, per designated training plan, before assuming job responsibilities.
  • Develops and manages schedules and performance requirements of staff.
  • Ensures compliance with company policies, including Privacy/HIPAA, and other legal and Regulatory requirements.
  • Other responsibilities as assigned.
Desired Qualifications
  • A Master’s degree in the same fields as listed above and/or an MBA or equivalent, preferred.
  • Advanced marketing and/or data science training, desired.
  • Experience in the diabetes industry, preferred.

Tandem Diabetes Care designs and sells insulin pumps and related software for people with diabetes. Its flagship product is the t:slim X2 insulin pump, a subcutaneous device that delivers insulin and can work with other diabetes management devices through interoperable technology. A key feature is Basal-IQ, which uses continuous glucose monitoring data to predict low blood sugar and pause insulin delivery to prevent hypoglycemia. The company generates revenue from selling pumps and accessories like infusion sets and cartridges, as well as software updates and subscriptions for advanced management features, creating recurring income. Tandem differentiates itself with interoperable hardware and software that aim to simplify diabetes care and integrate with other devices, not just sell a single pump. Its goal is to improve diabetes management and quality of life by providing user-friendly, connected insulin delivery and management solutions for patients aged six and older.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

2006

Simplify Jobs

Simplify's Take

What believers are saying

  • Pharmacy pay-as-you-go model doubles lifetime revenue per patient over four years.
  • Control-IQ+ FDA clearance for pregnancy expands type 1 market in 2026.
  • International expansion into Switzerland, Austria, UK lifts ASP by 20%.

What critics are saying

  • Infusion set shortages from sole supplier halt 20-30% shipments through Q3 2026.
  • Abbott Libre 3 closed-loop launches Q3 2026, diverting CGM users to tubeless.
  • Dexcom G7 standalone AID approval June 2026 obsoletes Tandem pump hardware.

What makes Tandem Diabetes Care unique

  • Control-IQ+ algorithm delivers +2 hours daily time-in-range versus competitors.
  • Cloud-based Tandem Source enables remote clinician workflows and payer insights.
  • Pipeline spans tubed t:slim X2, Mobi, and Sigi rechargeable patch pumps.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Tandem Diabetes Care who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Holidays

401(k) Company Match

Remote Work Options

Hybrid Work Options

Employee Stock Purchase Plan

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
Stock Titan
Mar 27th, 2026
Board asks shareholders to approve 3.26m-share increase; TNDM files proxy (TNDM).

Board asks shareholders to approve 3.26m-share increase; TNDM files proxy (TNDM). Filing Impact Filing Sentiment Rhea-AI Filing Summary. Tandem Diabetes Care is holding its 2026 Annual Meeting virtually on May 20, 2026 to vote on seven proposals, including election of nine directors, say-on-pay, an increase of 3,260,000 shares to the 2023 Long-Term Incentive Plan, certificate of incorporation amendments, and ratification of Ernst & Young LLP as auditor. The Record Date shows 68,504,233 shares outstanding as of March 23, 2026. The company reports 2025 business highlights including $1.015 billion in worldwide sales, over 126,000 pump shipments, and several product and regulatory milestones. Insights. Proxy seeks shareholder approval for governance and charter amendments alongside routine meeting items. The proxy presents six board-recommended proposals plus general meeting mechanics for the May 20, 2026 virtual meeting and discloses 68,504,233 shares outstanding as of March 23, 2026. Two charter amendments are proposed: a Section 141(k) removal amendment and an officer exculpation amendment tied to recent DGCL changes. Key dependencies include supermajority vote thresholds: the Section 141(k) and Officer Exculpation Amendments each require 66 2/3% approval. Subsequent filings will report vote results in a Form 8-K within four business days after the meeting. Board requests a 3,260,000-share increase to the 2023 equity plan and summarizes 2025 pay outcomes. The board proposes adding 3,260,000 shares to the 2023 Long-Term Incentive Plan and discloses current availability and activity metrics: 729,748 shares available as of March 16, 2026, a 2025 burn rate of 3.1%, and historical grants shown through March 16, 2026. The plan retains features such as minimum 12-month vesting, anti-repricing, clawback provisions, and director grant caps. Outcomes will hinge on shareholder approval; if not approved, the company states it may exhaust current reserves and be unable to grant customary awards thereafter. 03/27/2026 - 04:07 PM | / | / | / | / | / | / | / | / | / | Value of initial fixed $100 investment based on: | / | / | / | / | | Year | Summary Compensation Table Total for PEO(1) | / | CAP to PEO(1)(3) | / | Average Summary Compensation Table Total for Non-PEO NEOs(2) | / | Average CAP to Non-PEO NEOs(2)(3) | / | Total Shareholder Return(4) | / | Peer Group Total Shareholder Return TSR(4) | / | Net Income (loss) ($ in millions)(5) | / | Sales ($ in millions)(6) | | 2025 | $ | 6,858,503 | / | / | $ | 2,919,024 | / | / | $ | 1,970,448 | / | / | $ | 1,579,586 | / | / | $ | 22.97 | / | / | $ | 99.39 | / | / | $ | (204.7) | / | / | $ | 1,014.7 | / | | 2024 | $ | 8,526,238 | / | / | $ | 6,793,928 | / | / | $ | 1,945,074 | / | / | $ | 1,752,852 | / | / | $ | 60.43 | / | / | $ | 105.42 | / | / | $ | (96.0) | / | / | $ | 940.2 | / | | 2023 | $ | 4,651,603 | / | / | $ | 1,510,100 | / | / | $ | 1,497,536 | / | / | $ | 1,086,227 | / | / | $ | 49.62 | / | / | $ | 106.34 | / | / | $ | (222.6) | / | / | $ | 747.7 | / | | 2022 | $ | 6,378,515 | / | / | $ | (8,343,937) | / | / | $ | 1,746,125 | / | / | $ | (3,175,063) | / | / | $ | 75.41 | / | / | $ | 99.81 | / | / | $ | (94.6) | / | / | $ | 801.2 | / | | 2021 | $ | 5,739,882 | / | / | $ | 16,412,581 | / | / | $ | 1,616,639 | / | / | $ | 5,058,736 | / | / | $ | 252.51 | / | / | $ | 125.43 | / | / | $ | 15.6 | / | / | $ | 702.8 | / | 2) The non-PEO NEOs, for each year reported were as follows: - 2025: Elizabeth A. Gasser, Shannon Hansen, Mark D. Novara and Leigh A. Vosseller - 2024: Elizabeth A. Gasser, Jean-Claude Kyrillos, Susan M. Morrison, Mark D. Novara and Leigh A. Vosseller - 2023: David B. Berger, Elizabeth A. Gasser, Brian B. Hansen, Susan M. Morrison, Mark D. Novara and Leigh A. Vosseller - 2022: David B. Berger, Elizabeth A. Gasser, Brian B. Hansen, Susan M. Morrison and Leigh A. Vosseller - 2021: David B. Berger, Elizabeth A. Gasser, Brian B. Hansen, Susan M. Morrison and Leigh A. Vosseller | Year | Executive(s) | / | Summary Compensation Table Total | / | Deduct: Stock Awards Granted in Year | / | Add: Year-End Fair Value of Unvested Equity Awards Granted in Year* | / | Add: Change in Year-End Fair Value of Unvested Equity Awards Granted in Prior Years | / | Add: Change in Year-End Fair Value of Equity Awards Granted in Prior Years Which Vested in Year | / | CAP | / | / | / | / | | 2025 | PEO | / | $ | 6,858,503 | / | / | $ | (5,367,796) | / | / | $ | 5,240,252 | / | / | $ | (2,611,510) | / | / | $ | (1,200,425) | / | / | $ | 2,919,024 | / | / | / | / | / | | Non-PEO NEOs | / | $ | 1,970,448 | / | / | $ | (1,226,792) | / | / | $ | 1,197,646 | / | / | $ | (166,600) | / | / | $ | (195,116) | / | / | $ | 1,579,586 | / | / | / | / | / | | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | * The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant. 6) As required by Item 402(v) of Regulation S-K, we have determined that Sales is the Company-Selected Measure. * Annual sales for 2024, 2023 and 2022 include the effect of net sales recognized (deferred) of $30.2 million, ($25.1) million and ($3.5) million, respectively. This related to the accounting treatment associated with our Tandem Choice Program offering, which began in September 2022 and ended December 31, 2024, to provide a pathway to eligible t:slim X2 customers to ownership of our newest hardware platform, Tandem Mobi, for a fee when available. There was no comparative adjustment to pump sales in 2025. | Most Important Performance Measures Used to Link CAP to Company Performance: | | Sales | | Gross Margin | | Adjusted EBITDA Margin* | | New Product Launch Timing | | Customer Satisfaction | | / | We have not granted stock options, stock appreciation rights, or similar instruments with option-like features since 2022 and have no policies or practices to disclose pursuant to Item 402(x)(1) of Regulation S-K. Faq. What is Tandem Diabetes Care (TNDM) voting on at the 2026 annual meeting? The company asks shareholders to elect nine directors and vote on six additional items. These include say-on-pay, a 3,260,000 -share increase to the 2023 equity plan, two charter amendments, and ratification of Ernst & Young LLP as auditor. When and how will TNDM shareholders vote at the 2026 Annual Meeting? The virtual meeting is scheduled for May 20, 2026 at 3:00 p.m. Pacific time. Shareholders may vote by internet, telephone, mail, or during the webcast using the 16-digit control number or QR code provided in proxy materials. How many Tandem (TNDM) shares were outstanding for voting purposes? There were 68,504,233 shares of Common Stock outstanding as of the Record Date, March 23, 2026, and each share is entitled to one vote on meeting matters. What change to the 2023 Long-Term Incentive Plan is being proposed? The board proposes to increase the number of shares authorized under the 2023 Plan by 3,260,000 shares and describes governance features like a minimum 12-month vesting rule and a director grant cap of $750,000 per fiscal year. What voting thresholds apply to the charter amendments in the proxy for TNDM? Approval of the Section 141(k) Amendment and the Officer Exculpation Amendment each requires the affirmative vote of holders of at least 66 2/3% of outstanding common shares on the Record Date. What financial highlights from 2025 does Tandem disclose in the proxy? The proxy cites more than $1.015 billion in worldwide sales for 2025, record Q4 sales above $290 million, and over 126,000 annual pump shipments, along with product rollouts and an FDA clearance of Control-IQ+ for type 2 diabetes.

Yahoo Finance
Mar 15th, 2026
Tandem Diabetes expands Mobi insulin pump to Android, aiming for $1.1B in 2026 sales

Tandem Diabetes Care has expanded its Tandem Mobi automated insulin delivery system to compatible Android smartphones in the US, following FDA clearance in November 2025 and a limited release in December. The Android rollout broadens accessibility for Mobi users and strengthens the company's position in smartphone-based diabetes management. The expansion supports Tandem's investment thesis by widening accessibility and reinforcing ecosystem retention, though near-term pressures remain from flat renewal expectations and ongoing losses. Combined with October 2025's integration of t:slim X2 with Abbott's FreeStyle Libre 3 Plus CGM, the move demonstrates a broader connectivity strategy. Tandem's narrative projects $1.2 billion revenue and $14.4 million earnings by 2028, requiring 7.5% yearly revenue growth. The company's 2026 sales guidance stands at approximately $1.065 billion to $1.085 billion.

Yahoo Finance
Mar 2nd, 2026
Tandem hits record 58% margin, plans pharmacy shift and tubeless 'Toby' pump launch

Tandem Diabetes Care reported a record fourth-quarter gross margin of 58%, driven by pricing, rising Mobi volume and early pharmacy channel adoption. The company is transitioning US sales to a pharmacy pay-as-you-go model, creating a near-term $70–$80 million revenue headwind in 2026 but offering materially higher long-term reimbursement—approximately double over four years and four times monthly versus durable medical equipment. Tandem is expanding direct international sales in Switzerland, Austria and the UK, with an expected average selling price uplift of at least 20%. The company plans to submit its tubeless Mobi cartridge, nicknamed "Toby", to the FDA in Q2 for commercial rollout in the second half of the year. The device will be compatible with existing Mobi pumps.

MarketScreener
Feb 25th, 2026
Tandem Diabetes Care prices upsized $265M convertible notes offering due 2032

Tandem Diabetes Care has priced a $265 million private placement of convertible senior notes due 2032, up from the initially announced $200 million. The notes carry a 0.00% interest rate and will mature on 15 March 2032. The insulin delivery and diabetes technology company estimates net proceeds of approximately $256.7 million after deducting fees and expenses. Initial purchasers have an option to buy an additional $35 million in notes. The notes will be convertible at an initial rate of 27.0362 shares per $1,000 principal amount, equivalent to a conversion price of approximately $36.99 per share. This represents a 37.5% premium over Tandem's closing stock price of $26.90 on 24 February 2026. Tandem plans to use proceeds for capped call transactions costing $13.5 million and general corporate purposes including potential acquisitions and working capital. The offering is expected to close on 27 February 2026.

Yahoo Finance
Feb 23rd, 2026
Brown Capital Management sells Tandem Diabetes as revenue growth disappoints, profitability goals missed

Brown Capital Management has sold its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM), citing weaker-than-expected performance, according to its fourth quarter 2025 investor letter. The San Diego-based diabetes technology company, which develops insulin pumps with advanced automated delivery systems, faced increasing competition and greater market saturation amongst Type 1 diabetes patients. Revenue growth fell short of expectations whilst the company remained unprofitable throughout 2025. Tandem reported worldwide sales of $290 million in Q4 2025, representing 15% year-over-year growth. The stock closed at $24.57 per share on 20 February 2026, down 24.77% over the previous 52 weeks. The company has a market capitalisation of $1.666 billion, with 33 hedge funds holding positions at the end of Q4.